Asthma Clinical Trials

Find Asthma Clinical Trials Near You

WIthdrawal of DUpilumab in Severe Asthma: a Randomized Non-inferiority-controlled Trial

Status: Recruiting
Location: See all (29) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

Asthma management has been revolutionised by the development of biological therapies. Dupilumab is an anti-interleukin4 receptor marketed in 2020 for severe asthmatic patients with 2 exacerbations or more within the last 12 months. Although data showed that safety and efficacy of dupilumab are sustained when treatment is extended up to 3 years, no study has emerged regarding dupilumab discontinuation. This study aims to demonstrate the non-inferiority regarding strategy failure at 24 months of stopping dupilumab (intervention group) compared with its continuation (control group) in controlled asthma patients receiving this drug for at least 3 years.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adult patients ≥ 18 years old

• Treated with dupilumab for at least 36 months for severe asthma

• Well controlled asthma defined by an Asthma Control Questionnaire score ≥ 18 and 0 or 1 exacerbation within the year prior to the inclusion visit

Locations
Other Locations
France
CHU Amiens-Picardie
NOT_YET_RECRUITING
Amiens
CHR d'Angers
NOT_YET_RECRUITING
Angers
CH de Bayonne
NOT_YET_RECRUITING
Bayonne
CHU de Besançon
RECRUITING
Besançon
CHU de Brest
NOT_YET_RECRUITING
Brest
CHU de Caen
NOT_YET_RECRUITING
Caen
CH de Cannes
NOT_YET_RECRUITING
Cannes
CHU de Clermont-Ferrand
NOT_YET_RECRUITING
Clermont-ferrand
CHI de Créteil
NOT_YET_RECRUITING
Créteil
CHU de Dijon
RECRUITING
Dijon
CH Annecy Genevois
NOT_YET_RECRUITING
Epagny-metz-annecy
CHU Grenoble-Alpes
RECRUITING
La Tronche
Hôpital Kremlin Bicêtre
RECRUITING
Le Kremlin-bicêtre
CH Le Mans
NOT_YET_RECRUITING
Le Mans
Institut Coeur Poumon, CHU de Lille
RECRUITING
Lille
Hôpital Croix Rousse
RECRUITING
Lyon
Hôpital Avicenne
NOT_YET_RECRUITING
Paris
Hôpital Bichât
RECRUITING
Paris
Hôpital Européen Georges Pompidou
NOT_YET_RECRUITING
Paris
CHU de Bordeaux
NOT_YET_RECRUITING
Pessac
Hôpital Lyon Sud
NOT_YET_RECRUITING
Pierre-bénite
CHU de Reims
RECRUITING
Reims
CH de Roubaix
NOT_YET_RECRUITING
Roubaix
CHU de La Réunion
ACTIVE_NOT_RECRUITING
Saint-denis
CHU de Nantes
RECRUITING
Saint-herblain
Nouvel Hôpital Civil
RECRUITING
Strasbourg
Hôpital Foch
RECRUITING
Suresnes
Hôpital Tarbes Lourdes
NOT_YET_RECRUITING
Tarbes
CHU de Toulouse
RECRUITING
Toulouse
Contact Information
Primary
Laurent GUILLEMINAULT, Md, PhD
guilleminault.l@chu-toulouse.fr
0567771850
Time Frame
Start Date: 2025-12-15
Estimated Completion Date: 2029-12-31
Participants
Target number of participants: 205
Treatments
Experimental: Stopping dupilumab
The experimental strategy comprises stopping dupilumab with no dose-reducing or interval of time-increasing strategy from the day of inclusion/randomisation
No_intervention: Dupilumab continuation
Dupilumab continuation at the same dose and same interval as baseline
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Toulouse

This content was sourced from clinicaltrials.gov